Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00429039 · ClinicalTrials.gov registry record · Phase 2
A Study to Accelerate Immune System Recovery Following Stem Cell Transplantation
A Phase 2 study, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 21
- Enrollment target
NCT00429039 is a Phase 2 study that was terminated before completion, run by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University. The registered enrollment target is 21 participants.
The verdict
NCT00429039, a Phase 2 study, was terminated before completion, sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 21 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if pre-treating donor lymphocytes with an investigational drug known as L-leucyl-L-leucine methyl ester (LLME, prior to donor lymphocyte infusion (DLI) will improve the recovery of the immune system following stem cell transplant.
Interventions
- DRUG L-leucyl-L-leucine methyl ester (LLME)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2000-09 |
| Est. Completion | 2009-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00429039
The ClinicalTrials.gov registry entry for NCT00429039 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 21 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which L-leucyl-L-leucine methyl ester (LLME) is the first listed.
NCT00429039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00429039 about?
NCT00429039 is a clinical study titled "A Study to Accelerate Immune System Recovery Following Stem Cell Transplantation". The purpose of this study is to determine if pre-treating donor lymphocytes with an investigational drug known as L-leucyl-L-leucine methyl ester (LLME, prior to donor lymphocyte infusion (DLI) will improve the recovery of the immune system following stem cell transplant.
What is the current status of trial NCT00429039?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 21 participants. The study started on 2000-09. Estimated completion is 2009-08.
What interventions are being tested in trial NCT00429039?
The interventions under investigation include: L-leucyl-L-leucine methyl ester (LLME) (DRUG).
Who is sponsoring clinical trial NCT00429039?
This trial is sponsored by Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University, which has 138 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.